To include your compound in the COVID-19 Resource Center, submit it here.

Takeda, Zinfandel's AD test fails to deliver

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMMORROW trial of 0.8 mg pioglitazone (AD-4833) after a planned interim futility analysis showed

Read the full 304 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE